Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors

Medical and Pediatric Oncology

Volumn 30, Issue 2, 1998, Pages 110-116

  León, Pedro ^a,b   Jiménez, Miguel ^a   Barona, Pascual ^a   Sierrasesúmaga, Luis ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Anemia, cancer; Chemotherapy; Children; Recombinant human erythropoietin

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030670124     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199802)30:2<110::AID-MPO8>3.0.CO;2-L     Document Type: Article

References (34)

1. Henry DH: Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol Oncol Clin North Am 8:961-973, 1994.
2. Duhrsen U, Hosseld DK: Hematopoietic growth factors and the treatment of tumor-associated anemias. Ann Hematol 69:213-221, 1994.
3. Zucker S: Anemia in cancer. Cancer Invest 3:249-260, 1985.
4. Steinberg D: Anemia and cancer. CA Cancer J Clin 39:296-304, 1989.
5. Miller CB, Jones RJ, Piantadosi S, Abeloff MD. Spivak JL: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689-1692, 1990.
6. Skillings J, Sridhar F, Wong C, Paddock L: The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 16:22-25, 1993.
7. Walker RH: Special report: Transfusion risk. Am J Clin Pathol 88:374-378, 1987.
8. Klein HG: Immunologic aspects of blood transfusion. Semin Oncol 21 (suppl 3): 16-20, 1994.
9. Dodd RY: The risk of transfusion-transmitted infection. N Engl J Med 327:419-420, 1992.
10. Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VP, Janssen RS, Lewis F, Notari EP, Petersen LR: Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 333:1721-1725, 1995.
11. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correlation of anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316:73-78, 1987.
12. Fischl M, Galpin J, Levine J, Groopman JE, Henry DH. Kennedy P, Miles S, Robbins W, Starrett B, Zalusky A, Abels RI, Tsai HC, Rudnick SA: Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 322:1488-1493, 1990.
13. Klaesson S, Ringden O, Ljungman P, Lonnqvist B, Wennberg L: Reduced blood transfusion requirements after allogeneic bone marrow transplantation: results of a randomized, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 13: 397-402, 1994.
14. Murphy EA, Bell AL, Wojtulewski J, Brzeski M, Madhok R, Capell HA: Study of erythropoietin in treatment of anemia in patients with rheumatoid arthritis. Br Med J 30:1337-1338, 1994.
15. Abels R: Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A (suppl 2):S2-S8, 1993.
16. Cascinu S, Fedeli A, Del Ferro E, Catalano G: Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 12: 1058-1062, 1994.
17. Karnofsky DA, Abelmann WH, Kraver LF: The use of nitrogen mustards in the palliative treatment of carcinoma with particular reference to bronchogenic carcinoma. Cancer 1:634-669, 1948.
18. Locatelli F, Zecca M, Pedrazzoli P, Prete L, Quaglini S, Comoli P, De Stefano P, Beguin Y, Robustelli della Cuna G, Severi F, Cazzola M: Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 13:403-410, 1994.
19. Beguin Y, Yerna M, Loo M, Weber M, Fillet G: Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82:648-653, 1992.
20. Ludwig H, Fritz E, Leigeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84:1056-1063, 1994.
21. Ludwig H, Sundal E, Pecherstorfer M, Leitgeg C, Bauernhofer T, Beinhauer A, Samonigg H, Kappeler AW, Fritz E: Recombinant human erythropoietin for the correction of cancer associated anemia with and without cytotoxic chemotherapy. Cancer 76:2319-2329, 1995.
22. Falkson CI, Keren-Rosenberg S, Uys A, Falkson G, Stehens K, Vermaak WJH: Recombinant human erythropoietin in the treatment of cancer-related anaemia. Oncology 51:497-501, 1994.
23. Barlogie B, Beck T: Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 11:88-94, 1993.
24. Cascinu S, Fedeli A, Fedeli SL, Catalano G: Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. Br J Cancer 67:156-158, 1993.
25. Nenadov Beck M, Beck D: Recombinant erythropoietin in acute chemotherapy-induced anemia of children with cancer. Med Ped Oncol 25:17-21, 1995.
26. Kronberger M, Keck B, Zoubek A, Neophytou B, Bock A, Fritsch G, Gadner H, Henry D: Prevention of anemia with r-HuEPO in children with Ewing's sarcoma or osteogenic sarcoma. [Abstract]. Proc ASCO 14:258, 1995.
27. Spivak JL: Recombinant human erythropoietin and the anemia of cancer. Blood 84:997-1004, 1994.
28. Dessypris EN, Graber SE, Krantz SB, Stone WJ: Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood 72:2060-2065, 1988.
29. Ganser A, Bergmann M, Voelkers B, Gruntzmacher P, Scigalla P, Hoelzer D: In vivo effects of recombinant human erythropoietin on circulating human hematopoietic progenitor cells. Exp Hematol 17:433-435, 1989.
30. Oster W, Herrmann F, Gamm H, Zeile G, Lindeman A, Müller G, Brune T, Kraemer H-P. Mertelsmann R: Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 8:956-962, 1990.
31. Case DC, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR, Salmon SE, Silver RT, Storniolo AM, Wampler GL, Dooley CM, Larholt KM, Nelson RA, Abels RI: Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85:801-806, 1993.
32. Ludwig H, Fritz E, Hotzmann H, Hocker P, Gisslinger H, Barnas U: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693-1699, 1990.
33. Levin NW: Quality of life and hematocrit level. Am J Kidney Dis 20(suppl 1): 16-20, 1992.
34. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H: Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73:2535-2542, 1994.